More key development information attached.....hmmmm!
Quantum-Si Announces Commercial Availability of PlatinumTM, the World’s First Next-Generation Single-Molecule Protein Sequencing Platform
December 20 2022 - 08:00AM
Quantum-Si combines Time Domain Sequencing™ and Semiconductor Chip Technology to Advance Drug Discovery and Diagnostics and Accelerate Scientific Breakthroughs, Helping People to Live Healthier and Longer Lives
Company Appoints Life Science Veteran Grace Johnston, PhD, as Chief Commercial Officer
Key Takeaways:
The accessibility gained when using Platinum™ is expected to transform science and understanding of the proteome by unlocking unprecedented insights about the human body — just as the advent of next-generation DNA sequencing revolutionized our knowledge of the human genome over the past two decades. The elegant simplicity of this next-generation protein sequencing platform enables broad-scale access to proteomic data, positioning Platinum™ as a critical instrument for the future of proteomics research.
The world’s first proven protein sequencing technology is available immediately for ordering with shipments beginning in Q1 2023.
Grace Johnston, PhD, has been appointed as the Company’s Chief Commercial Officer to lead global sales and commercial activities.
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the commercial availability of Platinum™, the world’s first next-generation single-molecule protein sequencing platform. Platinum will be offered at an unprecedented low price-point of $70,000, while its small 19.5 inch by 8.5 inch footprint benchtop design is poised to greatly improve access to high-resolution protein sequencing data, ultimately accelerating breakthroughs across scientific disciplines—from drug discovery to biotech—and helping people live healthier and longer lives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221220005214/en/
Quantum-Si Appoints Life Science Veteran Grace Johnston, PhD, as Chief Commercial Officer (Photo: Business Wire)
Quantum-Si Appoints Life Science Veteran Grace Johnston, PhD, as Chief
The launch of Platinum marks Quantum-Si’s movement out of almost a decade of stealth innovation. The Company was founded in 2013 by world-renowned scientist, entrepreneur, and National Medal of Technology and Innovation recipient Dr. Jonathan Rothberg, an original pioneer of next generation genome sequencing. Jeff Hawkins was appointed CEO in October and brings extensive experience from the life-sciences and diagnostics space, including senior leadership positions at Illumina. With many on the leadership team having played an active role in the advent of next-generation sequencing technology, Quantum-Si is well positioned to disrupt the current state of protein sequencing.
“Next-generation protein sequencing represents the vanguard of new therapeutic discovery, however, no other company has met the promise of delivering an accessible single-molecule protein sequencing platform – until today,” said Jeff Hawkins, CEO of Quantum-Si. “Our ability to both discover and characterize potential protein targets has been critically limited by current technology. Platinum delivers on a decade’s long mission to dramatically improve access and scalability of single-molecule protein sequencing.”
$5-$10+ buyout?
Quantum-Si Announces Commercial Availability of PlatinumTM, the World’s First Next-Generation Single-Molecule Protein Sequencing Platform
December 20 2022 - 08:00AM
Quantum-Si combines Time Domain Sequencing™ and Semiconductor Chip Technology to Advance Drug Discovery and Diagnostics and Accelerate Scientific Breakthroughs, Helping People to Live Healthier and Longer Lives
Company Appoints Life Science Veteran Grace Johnston, PhD, as Chief Commercial Officer
Key Takeaways:
The accessibility gained when using Platinum™ is expected to transform science and understanding of the proteome by unlocking unprecedented insights about the human body — just as the advent of next-generation DNA sequencing revolutionized our knowledge of the human genome over the past two decades. The elegant simplicity of this next-generation protein sequencing platform enables broad-scale access to proteomic data, positioning Platinum™ as a critical instrument for the future of proteomics research.
The world’s first proven protein sequencing technology is available immediately for ordering with shipments beginning in Q1 2023.
Grace Johnston, PhD, has been appointed as the Company’s Chief Commercial Officer to lead global sales and commercial activities.
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the commercial availability of Platinum™, the world’s first next-generation single-molecule protein sequencing platform. Platinum will be offered at an unprecedented low price-point of $70,000, while its small 19.5 inch by 8.5 inch footprint benchtop design is poised to greatly improve access to high-resolution protein sequencing data, ultimately accelerating breakthroughs across scientific disciplines—from drug discovery to biotech—and helping people live healthier and longer lives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221220005214/en/
Quantum-Si Appoints Life Science Veteran Grace Johnston, PhD, as Chief Commercial Officer (Photo: Business Wire)
Quantum-Si Appoints Life Science Veteran Grace Johnston, PhD, as Chief
The launch of Platinum marks Quantum-Si’s movement out of almost a decade of stealth innovation. The Company was founded in 2013 by world-renowned scientist, entrepreneur, and National Medal of Technology and Innovation recipient Dr. Jonathan Rothberg, an original pioneer of next generation genome sequencing. Jeff Hawkins was appointed CEO in October and brings extensive experience from the life-sciences and diagnostics space, including senior leadership positions at Illumina. With many on the leadership team having played an active role in the advent of next-generation sequencing technology, Quantum-Si is well positioned to disrupt the current state of protein sequencing.
“Next-generation protein sequencing represents the vanguard of new therapeutic discovery, however, no other company has met the promise of delivering an accessible single-molecule protein sequencing platform – until today,” said Jeff Hawkins, CEO of Quantum-Si. “Our ability to both discover and characterize potential protein targets has been critically limited by current technology. Platinum delivers on a decade’s long mission to dramatically improve access and scalability of single-molecule protein sequencing.”
$5-$10+ buyout?
